Mariner
CAPR icon

Mariner’s Capricor Therapeutics CAPR Stock Holding History

Mariner’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,417
Closed -$469K – 3567
2026
Q1 		$469K Sell
15,417
-6,033
-28% -$161K ﹤0.01% 2535
2025
Q4 		$619K Buy
21,450
+7,841
+58% +$102K ﹤0.01% 2303
2025
Q3 		$98.1K Buy
+13,609
New +$100K ﹤0.01% 3363

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Mariner's CAPR Position: Q2 2026 in Review

Mariner sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 15,417 shares — an estimated $469K sold.

Mariner first reported a position in CAPR in Q3 2025 and held it in 3 quarters. The position peaked at $619K in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Mariner reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 15,417 Capricor Therapeutics shares in Q2 2026, an estimated $469K.
  • Mariner first reported a position in Capricor Therapeutics in Q3 2025 and held it in 3 quarters.
  • Mariner's Capricor Therapeutics position peaked at $619K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.